Study CL-QRX003-002 will test whole-body application of QRX003 in conjunction with off-label systemic therapy in ...

EMA grants orphan drug designation to Quoin Pharma’s QRX003 for the treatment of Netherton syndrome: Ashburn, Virginia Thursday, May 22, 2025, 15:00 Hrs [IST] Quoin Pharmaceutic ...

Company continues to advance QRX003 in late-stage clinical trials in Netherton Syndrome patients Regulatory milestone ...

QRX003 is being well tolerated by the patient and no adverse events have been reported. As a result of these positive initial ...

Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies ...

Announced Positive Clinical Data for Adult and Pediatric Netherton Patients ASHBURN, Va., May 13, 2025 (GLOBE NEWSWIRE) -- ...

Alzheimer’s disease is a progressive form of dementia that accounts for 60% to 80% of dementia cases, with most diagnoses occurring after age 65 years. Symptoms progress from mild memory changes ...

Hundreds of people in Canada are suspected to have come down with an unknown brain disease. But a new report suggests otherwise. © sfam_photo via Shutterstock ...

Next, I'm pleased to report that we received authorization to initiate patient enrollment for both the pipeline programs following ORLADEYO, BCX17725 in Netherton syndrome and avoralstat in ...

Key developments include: 1. BCX17225 for Netherton Syndrome: The company is progressing with clinical trials for this rare genetic skin disorder, with data expected later in the year. 2. Avoralstat ...

Key developments include: 1. BCX17225 for Netherton Syndrome: The company is progressing with clinical trials for this rare genetic skin disorder, with data expected later in the year. 2.